Compare Stocks: CBUS, CAPR, MNPR, and PROK

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$8.95 +0.1%	$7.53	$2.96 ▼ $40.37	$520.34M	0.61	3.46 million shs	2.55 million shs
CBUS Cibus	$1.71 +4.9%	$1.69	$1.09 ▼ $4.19	$130.69M	1.57	114,264 shs	247,441 shs
MNPR Monopar Therapeutics	$77.97	$107.25	$50.07 ▼ $124.82	$523.35M	1.5	141,327 shs	107,621 shs
PROK ProKidney	$1.72 +0.6%	$1.69	$1.30 ▼ $3.48	$520M	1.77	1.74 million shs	1.09 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	0.00%	+7.06%	-3.56%	-61.44%	+14.45%
CBUS Cibus	0.00%	+12.50%	+8.23%	+23.02%	+27.61%
MNPR Monopar Therapeutics	0.00%	-8.53%	-34.23%	-20.27%	-7.98%
PROK ProKidney	0.00%	+7.50%	-10.42%	-15.27%	-33.85%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CAPR Capricor Therapeutics	$8.95 +0.1%	$7.53	$2.96 ▼ $40.37	$520.34M	0.61	3.46 million shs	2.55 million shs
CBUS Cibus	$1.71 +4.9%	$1.69	$1.09 ▼ $4.19	$130.69M	1.57	114,264 shs	247,441 shs
MNPR Monopar Therapeutics	$77.97	$107.25	$50.07 ▼ $124.82	$523.35M	1.5	141,327 shs	107,621 shs
PROK ProKidney	$1.72 +0.6%	$1.69	$1.30 ▼ $3.48	$520M	1.77	1.74 million shs	1.09 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CAPR Capricor Therapeutics	0.00%	+7.06%	-3.56%	-61.44%	+14.45%
CBUS Cibus	0.00%	+12.50%	+8.23%	+23.02%	+27.61%
MNPR Monopar Therapeutics	0.00%	-8.53%	-34.23%	-20.27%	-7.98%
PROK ProKidney	0.00%	+7.50%	-10.42%	-15.27%	-33.85%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CAPR Capricor Therapeutics	2.27	Hold	$30.25	237.99% Upside
CBUS Cibus	2.00	Hold	$9.00	426.32% Upside
MNPR Monopar Therapeutics	2.82	Moderate Buy	$122.00	56.47% Upside
PROK ProKidney	2.67	Moderate Buy	$12.00	597.67% Upside

Current Analyst Ratings Breakdown

Latest CBUS, CAPR, MNPR, and PROK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/25/2026	CBUS Cibus	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/17/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/14/2026	CAPR Capricor Therapeutics	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$5.00 ➝ $21.00
9/11/2026	CAPR Capricor Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
9/11/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$128.00 ➝ $145.00
9/1/2026	CAPR Capricor Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/25/2026	CAPR Capricor Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform
8/17/2026	MNPR Monopar Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$130.00
8/14/2026	CAPR Capricor Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Neutral ➝ Overweight
8/13/2026	MNPR Monopar Therapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$125.00 ➝ $128.00

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CAPR Capricor Therapeutics	$22.27M	23.37	N/A	N/A	$5.53 per share	1.62
CBUS Cibus	$3.64M	35.91	N/A	N/A	$0.40 per share	4.28
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	$20.62 per share	N/A
PROK ProKidney	$890K	584.26	N/A	N/A	($3.36) per share	-0.51

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CAPR Capricor Therapeutics	-$105.04M	-$2.45	N/A	N/A	N/A	N/A	-56.60%	-43.97%	11/9/2026 (Estimated)
CBUS Cibus	-$127.08M	-$1.65	N/A	N/A	N/A	-2,258.89%	-287.03%	-27.99%	11/12/2026 (Estimated)
MNPR Monopar Therapeutics	-$13.72M	-$2.17	N/A	N/A	N/A	N/A	-13.08%	-12.79%	11/12/2026 (Estimated)
PROK ProKidney	-$68.99M	-$0.55	N/A	N/A	N/A	-10,288.39%	N/A	-27.39%	11/9/2026 (Estimated)

Latest CBUS, CAPR, MNPR, and PROK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CAPR Capricor Therapeutics	-$0.5889	-$0.70	-$0.1111	-$0.70	$2.08 million	N/A
8/13/2026	Q2 2026	CBUS Cibus	-$0.19	-$0.29	-$0.10	-$0.29	$1.70 million	$0.99 million
8/12/2026	Q2 2026	MNPR Monopar Therapeutics	-$0.6425	-$0.62	+$0.0225	-$0.7920	N/A	N/A
8/10/2026	Q2 2026	PROK ProKidney	-$0.14	-$0.15	-$0.01	-$0.15	$0.19 million	$0.15 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
CAPR Capricor Therapeutics	N/A	N/A	N/A	N/A	N/A
CBUS Cibus	N/A	N/A	N/A	N/A	N/A
MNPR Monopar Therapeutics	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CAPR Capricor Therapeutics	N/A	7.35	7.35
CBUS Cibus	N/A	1.62	1.62
MNPR Monopar Therapeutics	N/A	33.56	33.56
PROK ProKidney	N/A	8.36	8.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CAPR Capricor Therapeutics	21.68%
CBUS Cibus	33.81%
MNPR Monopar Therapeutics	1.83%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
CAPR Capricor Therapeutics	9.20%
CBUS Cibus	29.91%
MNPR Monopar Therapeutics	9.70%
PROK ProKidney	39.83%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CAPR Capricor Therapeutics	231	58.14 million	52.79 million	Optionable
CBUS Cibus	118	76.43 million	53.57 million	Optionable
MNPR Monopar Therapeutics	22	6.71 million	6.06 million	Not Optionable
PROK ProKidney	231	302.32 million	181.91 million	Optionable

CBUS, CAPR, MNPR, and PROK Headlines

Recent News About These Companies

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology’s Kidney Week 2026

October 2 at 2:24 PM | markets.businessinsider.com

ProKidney Announces Eight Abstracts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026

October 2 at 9:00 AM | globenewswire.com

ProKidney consensus price target increased by 22.40% to MX$116.87

September 29, 2026 | msn.com

ProKidney (NASDAQ:PROK) Stock Price Down 7.6% - Should You Sell?

September 21, 2026 | marketbeat.com

ProKidney (PROK) Stock Forecast & Price Target

September 19, 2026 | investing.com

ProKidney (NASDAQ:PROK) Trading 6% Higher - Still a Buy?

September 16, 2026 | marketbeat.com

ProKidney (PROK) Nears A Pivotal Kidney Therapy Verdict

September 11, 2026 | finance.yahoo.com

ProKidney (NASDAQ:PROK) Stock Price Up 7.6% - Should You Buy?

September 4, 2026 | marketbeat.com

ProKidney Corp. (PROK) Options Chain - Yahoo Finance

August 26, 2026 | finance.yahoo.com

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)

August 14, 2026 | seekingalpha.com

ProKidney (PROK) Receives a Hold from Morgan Stanley

August 14, 2026 | theglobeandmail.com

ProKidney (PROK) Receives a Hold from Morgan Stanley

August 14, 2026 | theglobeandmail.com

ProKidney (PROK) Gets a Buy from Guggenheim

August 12, 2026 | theglobeandmail.com

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

August 10, 2026 | zacks.com

ProKidney Reports Second Quarter 2026 Financial Results and Business Highlights

August 10, 2026 | manilatimes.netM

ProKidney Cell Therapy Thwarts Onerous Dialysis

July 30, 2026 | bloomberg.com

ProKidney Corp. (PROK) Latest Stock News & Headlines - Yahoo Finance

July 14, 2026 | finance.yahoo.com

ProKidney Corp (NASDAQ: PROK) - Share Price and Research

July 13, 2026 | intelligentinvestor.com.auI

What Makes ProKidney Corp (NASDAQ:PROK) Stand Out on Nasdaq Composite?

July 9, 2026 | kalkinemedia.comK

Why ProKidney (PROK) Is Building Its Bull Case Around Rilparencel’s Accelerated Approval Path

June 17, 2026 | insidermonkey.com

ProKidney names first chief technology officer as kidney therapy nears pivotal trial readout

June 2, 2026 | bizjournals.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

CBUS, CAPR, MNPR, and PROK Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

$8.95 +0.01 (+0.11%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$9.02 +0.07 (+0.74%)

As of 10/2/2026 07:59 PM Eastern

Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.

Cibus NASDAQ:CBUS

$1.71 +0.08 (+4.91%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.71 0.00 (0.00%)

As of 10/2/2026 07:30 PM Eastern

Cibus, Inc., a agricultural biotechnology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. Cibus, Inc. is based in San Diego, California.

Monopar Therapeutics NASDAQ:MNPR

$77.97 0.00 (0.00%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$77.84 -0.13 (-0.17%)

As of 10/2/2026 07:30 PM Eastern

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

ProKidney NASDAQ:PROK

$1.72 +0.01 (+0.58%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$1.74 +0.02 (+0.87%)

As of 10/2/2026 07:30 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CBUS, CAPR, MNPR, and PROK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CBUS, CAPR, MNPR, and PROK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CBUS, CAPR, MNPR, and PROK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CBUS, CAPR, MNPR, and PROK Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Cibus NASDAQ:CBUS

Monopar Therapeutics NASDAQ:MNPR

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest CBUS, CAPR, MNPR, and PROK Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest CBUS, CAPR, MNPR, and PROK Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

CBUS, CAPR, MNPR, and PROK Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

CBUS, CAPR, MNPR, and PROK Company Descriptions

Capricor Therapeutics NASDAQ:CAPR

Cibus NASDAQ:CBUS

Monopar Therapeutics NASDAQ:MNPR

ProKidney NASDAQ:PROK

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools